Mombasa, Kenya: The regulatory session at the 45th Annual Scientific Conference of the Pharmaceutical Society of Kenya (PSK), held on June 20, 2025, provided a dynamic platform for discussion on strengthening pharmaceutical regulation in Kenya. Chaired by Dr. F. M. Siyoi, Chief Executive Officer of the Pharmacy and Poisons Board (PPB), the session highlighted key regulatory developments and ongoing reforms.

In his opening remarks, PPB Chairman Dr. Charles Githinji reaffirmed the Board’s firm commitment to supporting pharmacists across all practice areas. “We are focused. We are listening. And I assure you—your concerns will be addressed through strong, responsive, and technically grounded leadership to make pharmacy thrive,” he stated.

Dr. Githinji emphasized several priorities driving the Board’s agenda, including enforcement of Good Pharmacy Practices, proper scheduling and classification of medicines, and active engagement with the Health Products and Technologies (HPTs) Bill currently before the Senate. “We are monitoring its progress to ensure that the voice of the pharmacy profession is reflected. Regulation is a core mandate of government, and I am personally committed to ensuring full implementation of the commitments we make,” he added.

The session featured strong participation from key PPB directorates—Health Products and Technologies, Corporate Services, and Pharmacy Practice—who outlined ongoing regulatory progress. Dr. Siyoi reiterated the Board’s dedication to elevating regulatory standards nationwide and noted that PPB is at an advanced stage in its pursuit of World Health Organization (WHO) Maturity Level 3 status.

Panel discussions, spotlighted priority actions underway to enhance service delivery and patient safety. These include proactive post-marketing surveillance, capacity-building in pharmacovigilance, initiation of bioequivalence studies, and development of regulatory frameworks to support specialization in pharmacy practice.

The session reinforced PPB’s position as a technically competent, stakeholder-driven institution committed to securing a safe, responsive, and accountable pharmaceutical sector.

Ends